Lilly captures 70% of new Medicare GLP-1 patients, CEO says
About 700,000 new Medicare beneficiaries have started GLP-1 treatment since the Medicare GLP-1 Bridge launched in July, and 70% of those patients are taking Eli Lilly medicines, Lilly CEO Dave Ricks told CNBC in a Sept. 21 interview. The Bridge program gives eligible Medicare Part D beneficiaries access to Zepbound, Foundayo and injectable or oral […] The post Lilly captures 70% of new Medicare GLP-1 patients, CEO says appeared first on Becker's Hospital Review | Healthcare News &...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.